UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2017

 

 

ALTIMMUNE, INC.

(Exact name of registrant as specified in its Charter)

 

 

 

Delaware   001-32587   20-2726770

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

19 Firstfield Road, Suite 200

Gaithersburg, Maryland

  20878
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) )

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) )

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01 Other Events

On May 16, 2017, Altimmune, Inc. (the “Company”) announced the appointment of Sybil Tasker, M.D., FACP, FIDSA, the Company’s Senior Vice President of Clinical Research and Development, as the Company’s Chief Medical Officer. A copy of the Company’s press release announcing Dr. Tasker’s appointment as Chief Medical Officer is attached hereto as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

  

Description of Exhibit

99.1

   Press release dated May 16, 2017

 

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 16, 2017     ALTTIMUNE INC.
    By:   /s/ William Enright
    Name:    William Enright
    Title:   Chief Executive Officer

 

3

EXHIBIT INDEX

 

Exhibit
Number

  

Description of Exhibit

99.1

   Press release dated May 16, 2017

 

4

Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Pharmathene, (delisted) Charts.
Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Pharmathene, (delisted) Charts.